RU2021101041A - PROTEIN-TYROSINPHOSPHATASE INHIBITORS AND METHODS OF THEIR APPLICATION - Google Patents

Claims (342)

1. Compound represented by formula (I)

(I) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, N -oxide, stereoisomer or isotopically enriched variant thereof, wherein: R ¹ is selected from the group consisting of hydrogen, halogen, C _1-6 alkyl, C _3-6 cycloalkyl, -OC _1-6 alkyl, -N(R ^a )-C _1-6 alkyl and -C _1-6 alkylene -5-6 membered heterocyclyl; where C _1-6 alkyl, C _3-6 cycloalkyl, -OC _1-6 alkyl, -N(R ^a )-C _1-6 alkyl and -C _1-6 alkylene-5-6 membered heterocyclyl may optionally be substituted at one or more available carbon atoms with one, two, three or more substituents each independently selected from R ^g ; and moreover, if -C _1-6 alkylene-5-6 membered heterocyclyl contains a substituted ring nitrogen atom, this ring nitrogen atom may optionally be substituted with R ^h ; R ² is selected from the group consisting of hydrogen, hydroxyl, -CHF ₂ , -CH ₂ OH, -CH ₂ CN, -CH ₂ -OC _1-6 alkyl, -CH ₂ -N(R ^a )-C _1-6 alkyl, C _2-6 alkyl, C _2-6 alkenyl, -OC _1-6 alkyl, -N(R ^a )-C _1-6 alkyl, -S(O) _w -C _1-6 alkyl, -C( O)-N(R ^a )-C _1-6 alkyl, -N(R ^a )-C(O)-C _1-6 alkyl, -OC(O)-N(R ^a )-C _1-6 alkyl , -N(R ^a )-C(O)-OC _1-6 alkyl, -C _3-6 cycloalkyl, -OC _3-6 cycloalkyl, C _1-6 alkylene-C _3-6 cycloalkyl, -C _1-6 alkenylene-C _3-6 cycloalkyl, -OC _1-6 alkylene-C _3-6 cycloalkyl, 5-6 membered heteroaryl, 4-6 membered heterocyclyl, -OC _1-6 alkylene-5-6 membered heteroaryl, -O-4 -6 membered heterocyclyl, -N(R ^a )-4-6 membered heterocyclyl, -C _1-6 alkylene-4-6 membered heterocyclyl and -OC _1-6 alkylene-4-6 membered heterocyclyl; where -CH ₂ -OC _1-6 alkyl, -CH ₂ -N(R ^a )-C _1-6 alkyl, C _2-6 alkyl, C _2-6 alkenyl, -OC _1-6 alkyl, -N(R ^a )-C _1-6 alkyl, -S(O) _w -C _1-6 alkyl, -C(O)-N(R ^a )-C _1-6 alkyl, -N(R ^a )-C(O )-C _1-6 alkyl, -OC(O)-N(R ^a )-C _1-6 alkyl, -N(R ^a )-C(O)-OC _1-6 alkyl, -C _3-6 cycloalkyl , -OC _3-6 cycloalkyl, -C _1-6 alkylene-C _3-6 cycloalkyl, -C _1-6 alkenylene-C _3-6 cycloalkyl, -OC _1-6 alkylene-C _3-6 cycloalkyl, 5-6 membered heteroaryl, -OC _1-6 alkylene-5-6 membered heteroaryl, 4-6 membered heterocyclyl, -O-4-6 membered heterocyclyl, -N(R ^a )-4-6 membered heterocyclyl, -C _1-6 alkylene -4-6 membered heterocyclyl and -OC _1-6 alkylene-4-6 membered heterocyclyl may optionally be substituted on one or more available carbon atoms with one, two, three or more substituents each independently selected from R ^g ; and moreover, if 5-6 membered heteroaryl, 4-6 membered heterocyclyl, -N(R ^a )-4-6 membered heterocyclyl, -C _1-6 alkylene-4-6 membered heterocyclyl or -OC _1-6 alkylene-4 -6 membered heterocyclyl contains a substituted ring nitrogen atom, this ring nitrogen atom may optionally be substituted with R ^h ; or R ¹ and R ² taken together with the atoms to which they are attached form a 5-6 membered aryl or heteroaryl; wherein aryl or heteroaryl may optionally be substituted with one or more substituents each independently selected from the group consisting of halo, hydroxyl, cyano, C _1-6 alkyl and C _1-6 alkoxy; where C _1-6 alkyl and C _1-6 alkoxy may optionally be substituted with one, two, three or more substituents each independently selected from R ^P ; R ³ is selected from the group consisting of hydrogen, -C _1-6 alkyl, -OC _1-6 alkyl, -N(R ^a )-C _1-6 alkyl, -S(O) _w -C _1-6 alkyl, -C(O)-N(R ^a )-C _1-6 alkyl, -N(R ^a )-C(O)-C _1-6 alkyl and -C _1-6 alkylene-4-6 membered heterocyclyl; where -C _1-6 alkyl, -OC _1-6 alkyl, -N (R ^a ) -C _1-6 alkyl, -S (O) _w -C _1-6 alkyl, -C (O) -N (R ^a )-C _1-6 alkyl, -N(R ^a )-C(O)-C _1-6 alkyl and -C _1-6 alkylene-4-6 membered heterocyclyl may optionally be substituted on one or more available carbon atoms one, two, three or more substituents each independently selected from R ^g ; and moreover, if -C _1-6 alkylene _-4-6 membered heterocyclyl contains a substituted ring nitrogen atom, this ring nitrogen atom may optionally be substituted with R ^h ; R ⁴ is selected from the group consisting of hydrogen, halogen, C _1-6 alkyl, C _3-6 cycloalkyl and -C _1-6 alkylene-4-6 membered heterocyclyl; where C _1-6 alkyl, C _3-6 cycloalkyl and -C _1-6 alkylene-4-6 membered heterocyclyl may optionally be substituted on one or more available carbon atoms with one, two, three or more substituents, each independently selected from R ^g ; and moreover, if -C _1-6 alkylene-4-6 membered heterocyclyl contains a substituted ring nitrogen atom, this ring nitrogen atom may optionally be substituted with R ^h ; where at least one of R ¹ , R ² , R ³ and R ⁴ is not hydrogen; R ⁵ is selected from the group consisting of hydrogen, halogen, C _1-6 alkyl, C _3-6 cycloalkyl and -C _1-6 alkylene-4-6 membered heterocyclyl; where C _1-6 alkyl, C _3-6 cycloalkyl and -C _1-6 alkylene-4-6 membered heterocyclyl may optionally be substituted on one or more available carbon atoms with one, two, three or more substituents, each independently selected from R ^g ; and moreover, if -C _1-6 alkylene-4-6 membered heterocyclyl contains a substituted ring nitrogen atom, this ring nitrogen atom may optionally be substituted with R ^h ; R ⁶ is hydrogen; R ⁷ is hydrogen; for each occurrence R ^g is independently selected from the group consisting of hydrogen, halogen, hydroxyl, cyano, nitro, oxo, -C(O)OH, R ^a R ^b N-, R ^a R ^b NC(O)-, R ^a R ^b N-SO _w -, R ^a R ^b NC(O)-N(R ^a )-, C _1-6 alkyl, C _2-6 alkenyl, C _2-6 alkynyl, C _3-6 cycloalkyl, phenyl, C _1-6 alkylene-C _3-6 cycloalkyl, -OC _1-6 alkylene-C _3-6 cycloalkyl, -(CO)-(NR ^a )-C _1-6 alkylene-C _3-6 cycloalkyl, C _{1- 6} alkoxy, C _3-6 alkenyloxy, C _3-6 alkynyloxy, C _3-6 cycloalkoxy, C _1-6 alkyl-C(O)-, C _1-6 alkyl-OC(O)-, C _1-6 alkyl -C(O)-O-, C _1-6 alkyl-S(O) _w -, C _1-6 alkyl-N(R ^a )-, C _1-6 alkyl-N(R ^a )-C(O )-, C _1-6 alkyl-C(O)-N(R ^a ), C _1-6 alkyl-N(R ^a )-C(O)-N(R ^a )-, C _1-6 alkyl- N(R ^a )-SO _w -, C _3-6 cycloalkyl-N(R ^a )-SO _w -, C _1-6 alkyl-SO _w -N(R ^a )-, C _3-6 cycloalkyl-SO _w -N(R ^a )-, 4-6 membered heterocyclyl-SO _w -N(R ^a )-, C _1-6 alkoxy-C(O)-N(R ^a )-, C _1-6 alkyl-C( O)-N(R ^a )-C _1-6 alkyl-, C _1-6 alkyl-N(R ^a )-C(O)-C _1-6 alkyl-, -P(O)(C _1-3 alkyl) ₂ and C _1-6 alkoxy-C _1-6 alkyl-; where C _1-6 alkyl, C _2-6 alkenyl, C _2-6 alkynyl, C _3-6 cycloalkyl, phenyl, C _1-6 alkylene-C _3-6 cycloalkyl, -OC _1-6 alkylene-C _3-6 cycloalkyl, -(CO)-(NR ^a )-C _1-6 alkylene-C _3-6 cycloalkyl, C _1-6 alkoxy, C _3-6 alkenyloxy, C _3-6 alkynyloxy, C _3-6 cycloalkoxy, C _{1 -6} alkyl-C(O)-, C _1-6 alkyl-OC(O)-, C _1-6 alkyl-C(O)-O-, C _1-6 alkyl-S(O) _w -, C _1-6 alkyl-N(R ^a )-, C _1-6 alkyl-N(R ^a )-C(O)-, C _1-6 alkyl-C(O)-N(R ^a ), C _{1- 6} alkyl-N(R ^a )-C(O)-N(R ^a )-, C _1-6 alkyl-N(R ^a )-SO _w -, C _3-6 cycloalkyl-N(R ^a )-SO _w -, C _1-6 alkyl-SO _w -N(R ^a )-, C _3-6 cycloalkyl-SO _w -N(R ^a )-, 4-6 membered heterocyclyl-SO _w -N(R ^a )- , C _1-6 alkoxy-C(O)-N(R ^a )-, C _1-6 alkyl-C(O)-N(R ^a )-C _1-6 alkyl-, C _1-6 alkyl-N (R ^a )-C(O)-C _1-6 alkyl-, -P(O)(C _1-3 alkyl) ₂ and C _1-6 alkoxy-C _1-6 alkyl- may optionally be substituted with one, two , three or more substituents each independently selected from R ^P ; for each occurrence, R ^h is independently selected from the group consisting of C _1-6 alkyl, C _3-6 alkenyl, C _3-6 alkynyl, C _3-6 cycloalkyl, -C _1-6 alkyl-C _3-6 cycloalkyl, C _1-6 alkyl-S(O) ₂ -, C _3-6 cycloalkyl-S(O) ₂ -, 4-6 membered heterocyclyl-S(O) ₂ -, 4-6 membered heterocyclyl-C _1-6 alkyl- S(O) ₂ -, 5-6 membered heteroaryl-S(O) ₂ -, phenyl-S(O) ₂ -, phenyl-C _1-6 alkyl-S(O) ₂ -, C _1-6 alkyl- C(O)-, C _1-6 cycloalkyl-C(O)-, C _1-6 alkoxy-C(O)-, R ^a R ^b NC(O)-, R ^a R ^b N-SO ₂ - and -P(O)(C _1-3 alkyl) ₂ ; where C _1-6 alkyl, C _3-6 alkenyl, C _3-6 alkynyl, C _3-6 cycloalkyl, -C _1-6 alkyl-C _3-6 cycloalkyl, C _1-6 alkyl-S(O) ₂ - , C _3-6 cycloalkyl-S(O) ₂ -, 4-6 membered heterocyclyl-S(O) ₂ -, 4-6 membered heterocyclyl-C _1-6 alkyl-S(O) ₂ -, 5-6 membered heteroaryl-S(O) ₂ -, phenyl-S(O) ₂ -, phenyl-C _1-6 alkyl-S(O) ₂ -, C _1-6 alkyl-C(O)-, C _1-6 cycloalkyl -C(O)-, C _1-6 alkoxy-C(O)-, R ^a R ^b NC(O)-, R ^a R ^b N-SO ₂ - and -P(O) (C _1-3 alkyl ) ₂ may optionally be substituted with one, two, three or more substituents each independently selected from R ^P ; for each occurrence, R ^p is independently selected from the group consisting of halogen, hydroxyl, cyano, C _1-6 alkyl, C _1-6 alkoxy, C _3-6 cycloalkyl, 4-6 membered heterocyclyl, R ^a R ^b N-, R ^a R ^b N-carbonyl-, R ^a R ^b N-SO ₂ - and R ^a R ^b N-carbonyl-N(R ^a )-; for each occurrence, R ^a and R ^b are independently selected from the group consisting of hydrogen, C _1-6 alkyl and C _3-6 cycloalkyl; where C _1-6 alkyl may optionally be substituted with one or more substituents, each independently selected from the group consisting of halogen, cyano, oxo, hydroxyl and C _1-6 alkoxy (optionally substituted with one, two or three fluorine atoms); or R ^a and R ^b together with the nitrogen to which they are attached form a 4-6 membered heterocyclyl, wherein the heterocyclyl may optionally be substituted with one or more substituents each independently selected from the group consisting of halo, cyano, oxo and hydroxyl; and w is 0, 1, or 2. 2. The compound according to claim 1, where one, two, three or more hydrogen atoms of the compound may optionally be deuterium atoms; and wherein all other atoms of the compound are present in their natural isotopic composition. 3. The compound according to claim 1 or 2, where one, two, three or more hydrogen atoms may optionally represent deuterium atoms in one, two, three or more groups, each of which is independently selected from R ¹ , R ² , R ⁴ , R ⁵ , R ⁶ , R ⁷ and R ^g . 4. Connection according to any one of paragraphs. 1-3, where R ¹ is selected from the group consisting of hydrogen, deuterium, chlorine and fluorine. 5. Connection according to any one of paragraphs. 1-4, where R ² is a 4-6 membered heterocyclyl; moreover, R ² may optionally be substituted on one or more available carbon atoms with one, two or three substituents, each of which is independently selected from R ^g , while if a 4-6-membered heterocyclyl contains a substituted ring nitrogen atom, this ring nitrogen atom may optionally be substituted with a substituent selected from R ^h . 6. Connection according to any one of paragraphs. 1-5, where R ² is a 4-6 membered heterocyclyl; where R ² may optionally be substituted on one or more available carbon atoms with one, two or three substituents, each independently selected from the group consisting of hydrogen and C _1-6 alkyl; and wherein, if R ² contains a substituted ring nitrogen atom, that ring nitrogen atom may optionally be substituted with a substituent selected from the group consisting of hydrogen, C _1-6 alkyl (optionally substituted with one, two or three fluorine atoms), -C _1-6 alkyl-C _3-6 cycloalkyl, C _1-6 cycloalkyl-C(O)-, C _1-6 alkyl-S(O) ₂ - (optionally substituted with cyano, methoxy or one, two or three fluorine atoms) , C _3-6 cycloalkyl-S(O) ₂ -, 4-6 membered heterocyclyl-S(O) ₂ -, 4-6 membered heterocyclyl-C _1-6 alkyl-S(O) ₂ -, 5-6 membered heteroaryl-S(O) ₂ -, phenyl-S(O) ₂ -, phenyl-C _1-6 alkyl-S(O) ₂ -(optionally substituted R ^a R ^b N-), and -P(O)( C _1-3 alkyl) ₂ . 7. Connection according to any one of paragraphs. 1-6, where R ² is selected from the group consisting of

. 8. Connection according to any one of paragraphs. 1-4, where R ² is a 5-6 membered heteroaryl; wherein R ² may optionally be substituted on one or more of the available carbon atoms with one, two or three substituents each independently selected from R ^g , wherein if R ² contains a substituted ring nitrogen atom, that ring nitrogen may optionally be substituted with a substituent selected from R ^h . 9. Connection under item 8, where R ² represents a 5-6-membered heteroaryl; wherein R ² may optionally be substituted on one or more available carbon atoms with one, two or three substituents each independently selected from the group consisting of hydrogen, cyano, C _1-6 alkyl, C _1-6 alkoxy and -P( O)(C _1-3 alkyl) ₂ ; and wherein, if R ² contains a substituted ring nitrogen atom, that ring nitrogen atom may optionally be substituted with a substituent selected from the group consisting of hydrogen, -C _1-6 alkyl-C _3-6 cycloalkyl and C _3-6 cycloalkyl- S(O) ₂ -. 10. The compound according to claim 8 or 9, where R ² is selected from the group consisting of

11. Connection according to any one of paragraphs. 1-4, where R ² is -OC _1-6 alkylene-4-6 membered heterocyclyl, wherein R ² may optionally be substituted on one or more available carbon atoms with one, two, or three substituents each independently selected from R ^g , and yet, if R ² contains a substituted ring nitrogen atom, this ring nitrogen atom may optionally be substituted with a substituent selected from R ^h . 12. The compound according to claim 11, where R ² is -OC _1-6 alkylene-4-6 membered heterocyclyl, and R ² may optionally be substituted on one or more available carbon atoms with one, two or three substituents, each of which independently selected from the group consisting of hydrogen, halogen and C _1-6 alkyl, and wherein, if R ² contains a substituted ring nitrogen atom, this ring nitrogen atom may optionally be substituted with a substituent selected from the group consisting of hydrogen, C _{1 -6} alkyl and C _1-6 alkyl-S(O) ₂ -. 13. The compound according to claim 11 or 12, where R ² is selected from the group consisting of

14. Connection according to any one of paragraphs. 1-4, where R ² represents -OC _1-6 alkylene-5-6 membered heteroaryl. 15. The compound according to claim 14, where R ² is selected from the group consisting of

,

,

and

. 16. Connection according to any one of paragraphs. 1-4, where R ² is selected from the group consisting of -C _2-6 alkyl, C _2-6 alkenyl and C _3-6 cycloalkyl; where R ² may optionally be substituted with one, two, three or more substituents, each independently selected from R ^g . 17. The compound according to claim 16, where R ² is selected from the group consisting of -C _2-6 alkyl, C _2-6 alkenyl, C _3-6 cycloalkyl, -C _1-6 alkylene-C _3-6 cycloalkyl and - C _1-6 alkenylene-C _3-6 cycloalkyl; where R ² may optionally be substituted with one, two, three or more substituents, each independently selected from the group consisting of cyano, chlorine, fluorine, hydroxyl, C _1-6 alkoxy, phenyl and R ^a R ^b N-. 18. The compound according to claim 16 or 17, where R ² is selected from the group consisting of

19. Connection according to any one of paragraphs. 1-4, where R ² represents -OC _1-6 alkyl; wherein R ² may optionally be substituted with one, two, three or more substituents each independently selected from R ^g . 20. The compound according to claim 19, where R ² represents -OC _1-6 alkyl; where R ² may optionally be substituted with one, two, three or more substituents, each independently selected from the group consisting of cyano, deuterium, chlorine, fluorine, hydroxyl, oxo, C _1-6 alkoxy, C _3-6 cycloalkoxy, -OC _1-6 alkylene-C _3-6 cycloalkyl, -(CO)-(NR ^a )-C _1-6 alkylene-C _3-6 cycloalkyl, C _1-6 alkyl-OC(O)-, R ^a R ^b N - (where R ^b with -OCH ₃ or -OCF ₃ ), C _1-6 alkyl-N(R ^a )-, R ^a R ^b NC(O)-, -P(O)(C _1-3 alkyl) ₂ , C _1-6 alkyl-N(R ^a )-C(O)-, C _1-6 alkyl-N(R ^a )-C(O)-N(R ^a )-, C _1-6 alkyl- SO ₂ -N(R ^a )-, C _3-6 cycloalkyl-SO ₂ -N(R ^a )- and 4-6 membered heterocyclyl-SO ₂ -N(R ^a )-. 21. The compound according to claim 19 or 20, where R ² is selected from the group consisting of

,

. 22. Connection according to any one of paragraphs. 1-4, where R ² represents -OC _3-6 cycloalkyl or -O-4-6 membered heterocyclyl; moreover, if R ² contains a substitutable ring nitrogen atom, this ring nitrogen atom may optionally be substituted with a substituent selected from R ^h . 23. The compound according to claim 22, where R ² represents -OC _3-6 cycloalkyl or -O-4-6 membered heterocyclyl; moreover, if R ² contains a substituted ring nitrogen atom, this ring nitrogen atom may optionally be substituted by a substituent selected from the group consisting of C _1-6 alkyl-SO ₂ -N(R ^a )- and C _3-6 cycloalkyl-SO ₂ -N(R ^a ) -. 24. The compound according to claim 22 or 23, where R ² is selected from the group consisting of

25. Connection according to any one of paragraphs. 1-4, where R ² represents -N(R ^a )-C _1-6 alkyl, and R ² may optionally be substituted with one, two or three substituents, each independently selected from R ^g . 26. The compound according to claim 25, where R ² represents -N(R ^a )-C _1-6 alkyl, where R ² may optionally be substituted with one, two or three substituents, each of which is independently selected from the group consisting of fluorine, -C(O)OH, cyano, oxo, R ^a R ^b N-, C _1-6 alkoxy, phenyl, -C _3-6 cycloalkyl, C _3-6 cycloalkyl-SO ₂ -N(R ^a )- and -(CO)-(NR ^a )-C _1-6 alkylene-C _3-6 cycloalkyl. 27. The compound according to claim 25 or 26, where R ² is selected from the group consisting of

28. Connection according to any one of paragraphs. 1-4, where R ² is -OC _1-6 alkylene-C _3-6 cycloalkyl, wherein R ² may optionally be substituted with one, two or three substituents each independently selected from R ^g . 29. The compound according to claim 28, where R ² is -OC _1-6 alkylene-C _3-6 cycloalkyl, and R ² may optionally be substituted with one, two or three substituents, each independently selected from the group consisting of fluorine, hydroxyl, R ^a R ^b N-, cyano, and C _1-3 alkyl; where C _1-3 alkyl may be optionally substituted with a substituent selected from the group consisting of cyano and C _1-3 alkoxy. 30. The compound according to claim 28 or 29, where R ² is selected from the group,

31. Connection according to any one of paragraphs. 1-4, where R ² represents -OC(O)-N(R ^a )-C _1-6 alkyl. 32. The compound according to claim 31, where R ² is

. 33. Connection according to any one of paragraphs. 1-4, where R ² represents -N(R ^a )-4-6 membered heterocyclyl, and, if R ² contains a substituted ring nitrogen atom, this ring nitrogen atom may optionally be substituted with a substituent selected from R ^h . 34. The compound according to claim 33, where R ² is -N(R ^a )-4-6 membered heterocyclyl, and, if R ² contains a substituted ring nitrogen atom, this ring nitrogen atom may optionally be substituted with a substituent selected from the group , consisting of C _1-6 alkyl-SO ₂ -N(R ^a )- and C _3-6 cycloalkyl-SO ₂ -N(R ^a )-. 35. The compound according to claim 33 or 34, where R ² is selected from the group,

36. Connection according to any one of paragraphs. 1-4, where R ² represents -C _1-6 alkylene-4-6 membered heterocyclyl, and, if R ² contains a substituted ring nitrogen atom, this ring nitrogen atom may optionally be substituted with a substituent selected from R ^h . 37. The compound according to claim 36, R ² is -C _1-6 alkylene-4-6 membered heterocyclyl, and if R ² contains a substituted ring nitrogen atom, this ring nitrogen atom may optionally be substituted with a substituent selected from the group, consisting of C _1-6 alkyl, C _1-6 alkyl-SO ₂ -N(R ^a )- and C _3-6 cycloalkyl-SO ₂ -N(R ^a )-, while C _1-6 alkyl may optionally be substituted by one, two or three fluorine atoms. 38. The compound according to claim 36 or 37, where R ² is selected from the group consisting of

,

,

,

,

,

,

and

. 39. Connection according to any one of paragraphs. 1-4, where R ² is selected from the group consisting of

. 40. A compound according to claim 1 wherein R ¹ and R ² taken together with the atoms to which they are attached form a 5-membered heteroaryl. 41. The compound according to claim 40, where R ¹ and R ² taken together with the atoms to which they are attached form furanyl. 42. The compound according to claim 40 or 41, characterized in that the compound is represented by:

. 43. Connection according to any one of paragraphs. 1-42, where R ³ represents hydrogen. 44. Connection according to any one of paragraphs. 1-43, where R ⁴ represents hydrogen. 45. Connection according to any one of paragraphs. 1-44, where R ⁵ is selected from the group consisting of hydrogen, deuterium, bromine, chlorine and fluorine. 46. Connection according to any one of paragraphs. 1-45, where R ⁶ is selected from the group consisting of hydrogen and deuterium. 47. Connection according to any one of paragraphs. 1-46, where R ⁷ is selected from the group consisting of hydrogen and deuterium. 48. Connection according to any one of paragraphs. 1-47, characterized in that all atoms of the compound are present in their natural isotopic composition. 49. Compound represented by formula (II)

(II) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, N -oxide or stereoisomer thereof, wherein: X is selected from the group consisting of -O- and -N(R ^a )-; L is straight or branched C _1-6 alkylene; R ^{2-II is} selected from the group consisting of hydrogen, cyano, -NR ^a R ^b , C _1-2 alkoxy, C _3-6 cycloalkyl-SO ₂ -N(R ^a )-, C _1-6 alkyl-SO ₂ -N(R ^a )-, phenyl, 5-6 membered heteroaryl, 4-6 membered heterocyclyl and C _3-6 cycloalkyl; wherein phenyl, 5-6 membered heteroaryl, 4-6 membered heterocyclyl and C _3-6 cycloalkyl may optionally be substituted on one or more available carbon atoms with one, two or three substituents each independently selected from the group consisting of halogen, hydroxyl, -NR ^a R ^b , C _1-2 alkyl (optionally substituted with one, two or three halogens) and C _1-2 alkoxy (optionally substituted with one, two or three halogens); and wherein, if the 5-6 membered heteroaryl or 4-6 membered heterocyclyl contains a substituted ring nitrogen atom, that ring nitrogen atom may optionally be substituted with C _1-3 alkyl; R ⁵ is selected from the group consisting of hydrogen, deuterium and halogen; R ⁶ is selected from the group consisting of hydrogen and deuterium; R ⁷ is selected from the group consisting of hydrogen and deuterium; and for each occurrence, each R ^a and R ^b is independently selected from the group consisting of hydrogen and C _1-3 alkyl. 50. The compound of claim 49 wherein X is selected from the group consisting of -O-, -N(H)- and -N(CH ₃ )-. 51. The compound according to claim 49 or 50, where L is selected from the group consisting of

,

,

,

,

and

; where * and # represent the covalent points of attachment to R ^2-II and X, respectively. 52. Connection according to any one of paragraphs. 49-51, where R ^{2-II is} selected from the group consisting of hydrogen, cyano, -NH ₂ , -N(CH ₃ ) ₂ , -

53. Connection according to any one of paragraphs. 49-52, where R ⁵ is selected from the group consisting of hydrogen, deuterium and fluorine. 54. Compound represented by formula (III)

(III); or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, N -oxide or stereoisomer thereof, wherein: X ^III is selected from the group consisting of a bond, -CH ₂ -, -NR ^a -, -O-, -O-CH ₂ - and -OCH ₂ -CH ₂ - m is 1, 2 or 3; n is 1, 2 or 3; R ^{1-III is} selected from the group consisting of hydrogen, halogen, hydroxyl, cyano, -NR ^a R ^b , C _1-2 alkyl (optionally substituted with one, two or three halogens) and C _1-2 alkoxy (optionally substituted with one, two or three halogens); R ^{2-III is} selected from the group consisting of hydrogen, C _1-4 alkyl, -C(O)-C _1-4 alkyl, -C(O)-OC _1-4 alkyl, -C(O)-N( R ^a )-C _1-4 alkyl, -S(O) ₂ -C _1-4 alkyl and -S(O) ₂ -C _3-6 cycloalkyl; where C _1-4 alkyl, -C(O)-C _1-4 alkyl, -C(O)-OC _1-4 alkyl, -C(O)-N(R ^a )-C _1-4 alkyl, - S(O) ₂ -C _1-4 alkyl and -S(O) ₂ -C _3-6 cycloalkyl may optionally be substituted with one, two or three substituents, each independently selected from the group consisting of halogen, hydroxyl, cyano, - NR ^a R ^b , C _1-2 alkyl (optionally substituted with one, two or three halogens) and C _1-2 alkoxy (optionally substituted with one, two or three halogens); R ⁵ is selected from the group consisting of hydrogen, deuterium and halogen; R ⁶ is selected from the group consisting of hydrogen and deuterium; R ⁷ is selected from the group consisting of hydrogen and deuterium; and for each occurrence, each R ^a and R ^b is independently selected from the group consisting of hydrogen and C _1-3 alkyl. 55. The compound according to claim 54, where X ^III is selected from the group consisting of a bond, -CH ₂ , -O-, -NH- and -O-CH ₂ -. 56. The compound according to claim 54 or 55, where R ^{2-III is} selected from the group consisting of hydrogen, isopropyl, -CH ₂ CF ₃ , -S(O) ₂ -CH ₃ and -S(O) ₂ -cyclopropyl. 57. Connection according to any one of paragraphs. 54-56, where R ⁵ is selected from the group consisting of hydrogen, deuterium and fluorine. 58. A compound selected from the group consisting of: 5-{1-fluoro-3-hydroxy-7-[2-(morpholin-4-yl)ethoxy]naphthalene-2-yl}-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-{7-[1-(cyclopropanesulfonyl)pyrrolidin-3-yl]-1-fluoro-3-hydroxynaphthalene-2-yl}-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-[1-fluoro-3-hydroxy-7-(pyrrolidin-3-yl)naphthalen-2-yl]-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ ⁶ ,2,5-thiadiazolidin-2-yl)naphthalene-2-yl propan-2-ylcarbamate; 5-(9-fluoro-7-hydroxynaphtho[2,1- b ]furan-8-yl)-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-{7-[2-(azetidin-1-yl)ethoxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-[1-fluoro-3-hydroxy-7-methoxy( ^4-2 H)naphthalen- _{2-yl](4,4-2 H 2} ⁾ -1λ ^6,2,5 -thiadiazolidin-1,1,3 -trione; 5-[1-fluoro-3-hydroxy-7-(methylamino)naphthalen-2-yl]-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-{1-fluoro-3-hydroxy-7-[2-(piperidin-4-yl)ethoxy]naphthalene-2-yl}-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-(1-fluoro-7-{[3-fluoro-1-(propan-2-yl)pyrrolidin-3-yl]methoxy}-3-hydroxynaphthalen-2-yl)-1λ ⁶ ,2,5-thiadiazolidine -1,1,3-trione; 5-{1-fluoro-7-[(3-fluoropyrrolidin-3-yl)methoxy]-3-hydroxynaphthalene-2-yl}-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ ⁶ ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}pentanenitrile; 5-{1-fluoro-3-hydroxy-7-[2-(piperidin-1-yl)ethoxy]naphthalen-2-yl}-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-{7-[1-(cyclopropanesulfonyl)-2,5-dihydro-1 H -pyrrol-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ ⁶ ,2,5-thiadiazolidin- 1,1,3-trione; 5-{1-fluoro-3-hydroxy-7-[(piperidin-4-yl)methoxy]naphthalene-2-yl}-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ ⁶ ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}-3,3-dimethylpentanenitrile ; 5-{7-[(3,3-dimethylbutyl)amino]-1-fluoro-3-hydroxynaphthalene-2-yl}-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-(1,4-difluoro-3-hydroxy-7-methoxynaphthalen-2-yl)-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-{1-fluoro-3-hydroxy-7-[( ² H ₃ )methyloxy]naphthalen-2-yl}-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-[1-fluoro-3-hydroxy-7-(2-methoxyethoxy)naphthalene-2-yl]-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 4-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ ⁶ ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}-2,2-dimethylbutanenitrile ; 5-{7-[2-(3-aminobicyclo[1.1.1]pentan-1-yl)ethoxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ ⁶ ,2,5-thiadiazolidin-1, 1,3-trione; 5-(7-{[2-(dimethylamino)ethyl]amino}-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-(1-fluoro-3-hydroxy-7-methoxynaphthalene- _{2-yl)(4,4-2 H 2} ⁾ -1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-(1-fluoro-3-hydroxy-7-methoxynaphthalen-2-yl)-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; N- (2-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ ⁶ ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]amino}ethyl)cyclopropanesulfonamide ; 5-(1-fluoro-3-hydroxy-7-{[1-(methanesulfonyl)pyrrolidin-3-yl]amino}naphthalen-2-yl)-1λ ⁶ ,2,5-thiadiazolidin-1,1,3- trione; N- (2-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ ⁶ ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}ethyl)cyclopropanesulfonamide 5-(1-fluoro-3-hydroxy-7-{[1-(methanesulfonyl)azetidin-3-yl]amino}naphthalene-2-yl)-1λ ⁶ ,2,5-thiadiazolidin-1,1,3- trione; 4-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ ⁶ ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}butanenitrile; [1-({[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ ⁶ ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}methyl)cyclopropyl] acetonitrile; 5-{7-[2-(dimethylamino)ethoxy]-1-fluoro-3-hydroxynaphthalene-2-yl}-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-{7-[1-(cyclopropylmethyl)-1 H -pyrazol-4-yl]-1-fluoro-3-hydroxynaphthalene-2-yl}-1λ ⁶ ,2,5-thiadiazolidin-1,1,3- trione; 5-{1-fluoro-3-hydroxy-7-[( 1H -pyrazol-4-yl)methoxy]naphthalene-2-yl}-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-[1-fluoro-3-hydroxy-7-(2-methylpropoxy)naphthalen-2-yl]-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-[1-fluoro-3-hydroxy-7-(2-hydroxypropoxy)naphthalene-2-yl]-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; N- (cyclopropylmethyl)-8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ ⁶ ,2,5-thiadiazolidin-2-yl)naphthalene-2-carboxamide; 5-[1-fluoro-3-hydroxy-7-(2-{[2-(trifluoromethoxy)ethyl]amino}ethoxy)naphthalen-2-yl]-1λ ⁶ ,2,5-thiadiazolidin-1,1,3 -trione; 5-(1-fluoro-3-hydroxy-7-{2-[(2-methoxyethyl)amino]ethoxy}naphthalene-2-yl)-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-{1-fluoro-3-hydroxy-7-[3-(methylamino)propyl]naphthalene-2-yl}-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-{7-[3-(ethylamino)propyl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-{7-[5-(dimethylphosphoryl)thiophen-2-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-{7-[2-(cyclopropylamino)ethoxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-{1-fluoro-3-hydroxy-7-[2-(methylamino)ethoxy]naphthalene-2-yl}-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-{7-[2-(ethylamino)ethoxy]-1-fluoro-3-hydroxynaphthalene-2-yl}-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-(1-fluoro-3-hydroxy-7-{2-[(propan-2-yl)amino]ethoxy}naphthalen-2-yl)-1λ ⁶ ,2,5-thiadiazolidin-1,1,3- trione; 5-{7-[3-(diethylphosphoryl)propoxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-{1-fluoro-3-hydroxy-7-[(3 S )-3-hydroxybutoxy]naphthalene-2-yl}-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-{1,4-difluoro-3-hydroxy-7-[(3-methylbutyl)amino]naphthalene-2-yl}-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-{1-fluoro-3-hydroxy-7-[(3 R )-3-hydroxybutoxy]naphthalene-2-yl}-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-[7-(2-cyclopropyl-2-hydroxyethoxy)-1-fluoro-3-hydroxynaphthalene-2-yl]-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-{1-fluoro-3-hydroxy-7-[(4 R )-4-hydroxypentyl]naphthalene-2-yl}-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-{1-fluoro-3-hydroxy-7-[(4 R )-4-hydroxypentyl]naphthalene-2-yl}-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-{1-fluoro-3-hydroxy-7-[(4 S )-4-hydroxypentyl]naphthalene-2-yl}-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-[1-fluoro-3-hydroxy-7-(4-hydroxy-4-methylpentyl)naphthalen-2-yl]-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-{1-fluoro-3-hydroxy-7-[(3-oxopentyl)oxy]naphthalene-2-yl}-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-[1-fluoro-3-hydroxy-7-(3-hydroxybutoxy)naphthalen-2-yl]-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; N- [8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ ⁶ ,2,5-thiadiazolidin-2-yl)naphthalene-2-yl]-3-methylbutanamide; 5-[1-fluoro-3-hydroxy-7-(4,4,4-trifluorobutoxy)naphthalene-2-yl]-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 1-(2-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ ⁶ ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}ethyl)cyclopropane -1-carbonitrile; 5-(1-fluoro-3-hydroxy-7-{2-[1-(methoxymethyl)cyclopropyl]ethoxy}naphthalen-2-yl)-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-(7-{[(cyclopropylmethyl)amino]methyl}-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-{7-[(2,2-difluoropropyl)amino]-1-fluoro-3-hydroxynaphthalene-2-yl}-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-{7-[3,3-dimethyl-4-(methylamino)butoxy]-1-fluoro-3-hydroxynaphthalene-2-yl}-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-{1-fluoro-3-hydroxy-7-[(2-phenylethyl)amino]naphthalene-2-yl}-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-[7-(3-amino-3-methylbutoxy)-1-fluoro-3-hydroxynaphthalene-2-yl]-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-{1-fluoro-3-hydroxy-7-[(4,4,4-trifluorobutyl)amino]naphthalen-2-yl}-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-[7-(difluoromethyl)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-{7-[1-(dimethylphosphoryl)-2,5-dihydro-1 H -pyrrol-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ ⁶ ,2,5-thiadiazolidin- 1,1,3-trione; 5-{1-fluoro-3-hydroxy-7-[(3,3,3-trifluoropropyl)amino]naphthalen-2-yl}-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-[1-fluoro-3-hydroxy-7-(3-methoxy-3-methylbutoxy)naphthalen-2-yl]-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-[7-(2-cyclopropylpropoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-[1-fluoro-3-hydroxy-7-({2-[(propan-2-yl)oxy]ethyl}amino)naphthalene-2-yl]-1λ ⁶ ,2,5-thiadiazolidin-1,1 ,3-trion; 5-(1-fluoro-3-hydroxy-7-{[1-(methanesulfonyl)pyrrolidin-3-yl]methoxy}naphthalen-2-yl)-1λ ⁶ ,2,5-thiadiazolidin-1,1,3- trione; 4-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ ⁶ ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]amino}butanenitrile; 5-[1-fluoro-3-hydroxy-7-(2-hydroxyethyl)naphthalene-2-yl]-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-[7-(4-amino-3,3-dimethylbutoxy)-1-fluoro-3-hydroxynaphthalene-2-yl]-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-(7-{[2-(azetidin-1-yl)ethyl]amino}-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione ; 5-(7-{[1-(cyclopropanesulfonyl)azetidin-3-yl]oxy}-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione ; 5-{1-fluoro-3-hydroxy-7-[(2-methoxyethyl)amino]naphthalen-2-yl}-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-[1-fluoro-3-hydroxy-7-(3,3,3-trifluoropropoxy)naphthalene-2-yl]-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 1-({[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ ⁶ ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]amino}methyl)cyclopropan-1 -carbonitrile; 5-[1-fluoro-3-hydroxy-7-(3-hydroxy-3-methylbutoxy)naphthalen-2-yl]-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-{1-fluoro-3-hydroxy-7-[3-(1 H -pyrazol-1-yl)propoxy]naphthalene-2-yl}-1λ ⁶ ,2,5-thiadiazolidin-1,1,3- trione; 5-(7-{1-[(4-Aminophenyl)methanesulfonyl]-2,5-dihydro- 1H -pyrrol-3-yl}-1-fluoro-3-hydroxynaphthalene-2-yl)-1λ ⁶ .2 ,5-thiadiazolidin-1,1,3-trione; 5-[1-fluoro-3-hydroxy-7-(hydroxymethyl)naphthalene-2-yl]-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-{7-[1-(cyclopropanesulfonyl)piperidin-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-{7-[1-(cyclopropanecarbonyl)pyrrolidin-2-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-{1-fluoro-3-hydroxy-7-[2-(1 H -pyrazol-1-yl)ethoxy]naphthalen-2-yl}-1λ ⁶ ,2,5-thiadiazolidin-1,1,3- trione; 5-{7-[1-(cyclopropanesulfonyl)pyrrolidin-2-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-{7-[1-(cyclopropanesulfonyl)pyrrolidin-2-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-[1-fluoro-3-hydroxy-7-(piperidin-3-yl)naphthalen-2-yl]-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-{7-[2-(2,2-difluorocyclopropyl)ethoxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-{1-fluoro-3-hydroxy-7-[2-(1-methylcyclopropyl)ethoxy]naphthalene-2-yl}-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-(7-{1-[(3-Aminophenyl)methanesulfonyl]-2,5-dihydro- 1H -pyrrol-3-yl}-1-fluoro-3-hydroxynaphthalene-2-yl)-1λ ⁶ .2 ,5-thiadiazolidin-1,1,3-trione; 5-(7-{1-[(2-Aminophenyl)methanesulfonyl]-2,5-dihydro- 1H -pyrrol-3-yl}-1-fluoro-3-hydroxynaphthalene-2-yl)-1λ ⁶ .2 ,5-thiadiazolidin-1,1,3-trione; 5-[7-(2,2-difluoroethyl)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-[1-fluoro-3-hydroxy-7-(2,2,2-trifluoroethoxy)naphthalene-2-yl]-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-[1-fluoro-7-(2-fluoroethoxy)-3-hydroxynaphthalen-2-yl]-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 1-({[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ ⁶ ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}methyl)cyclopropan-1 -carbonitrile; 5-{1-fluoro-3-hydroxy-7-[(3-methylbutyl)amino]naphthalene-2-yl}-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-{1-fluoro-3-hydroxy-7-[(2-methylpropyl)amino]naphthalene-2-yl}-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-{7-[(cyclopropylmethyl)amino]-1-fluoro-3-hydroxynaphthalene-2-yl}-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; {[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ ⁶ ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}acetonitrile; 5-[1-fluoro-3-hydroxy-7-(3-methylbutoxy)naphthalen-2-yl]-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-(1,8-difluoro-3-hydroxy-7-methoxynaphthalen-2-yl)-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-{7-[1-(cyclopropanesulfonyl)azetidin-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-{7-[1-(cyclopropanecarbonyl)azetidin-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; (2 E )-3-[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ ⁶ ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]prop-2- ennitrile; 5-[7-(2-cyclopropylethyl)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-{7-[(2,2-difluorocyclopropyl)methoxy]-1-fluoro-3-hydroxynaphthalene-2-yl}-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-[7-(2-cyclopropylethoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-{7-[2-(cyclopropylmethoxy)ethoxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-{1-fluoro-3-hydroxy-7-[2-(oxolan-2-yl)ethoxy]naphthalene-2-yl}-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-{7-[2-(cyclobutyloxy)ethoxy]-1-fluoro-3-hydroxynaphthalene-2-yl}-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-(1-fluoro-3-hydroxy-7-{2-[(propan-2-yl)oxy]ethoxy}naphthalene-2-yl)-1λ ⁶ ,2,5-thiadiazolidin-1,1,3- trione; 5-[7-(3-ethoxypropoxy)-1-fluoro-3-hydroxynaphthalene-2-yl]-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-[7-(2- tert -Butoxyethoxy)-1-fluoro-3-hydroxynaphthalene-2-yl]-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-(7-{[ rac -(1 R ,2 R )-2-ethylcyclopropyl]methoxy}-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ ⁶ ,2,5-thiadiazolidin-1,1, 3-trione; 5-[1-fluoro-3-hydroxy-7-(4-methylpentyl)naphthalene-2-yl]-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-{7-[3-(2,2-dimethylpropyl)pyrrolidin-1-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ ⁶ ,2,5-thiadiazolidin-1,1,3- trione; 5-[7-(1-chloro-3-hydroxypropan-2-yl)-1-fluoro-3-hydroxynaphthalene-2-yl]-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-{7-[1-(cyclopropylmethyl)pyrrolidin-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-[7-(cyclopropyloxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-{7-[(2-cyclopropylethyl)amino]-1-fluoro-3-hydroxynaphthalene-2-yl}-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-[1-fluoro-3-hydroxy-7-(4-methyl-1 H -imidazol-2-yl)naphthalen-2-yl]-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione ; 5-[7-(azetidin-3-yl)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-[1-fluoro-3-hydroxy-7-(5-methoxythiophen-2-yl)naphthalen-2-yl]-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; [8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ ⁶ ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]acetonitrile; 5-[1-fluoro-3-hydroxy-7-(methoxymethyl)naphthalen-2-yl]-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-{1-fluoro-3-hydroxy-7-[(3-methyloxetan-3-yl)methoxy]naphthalene-2-yl}-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-{4-bromo-7-[1-(cyclopropanesulfonyl)-2,5-dihydro- 1H -pyrrol-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ ⁶ .2, 5-thiadiazolidin-1,1,3-trione; 5-{4-bromo-7-[1-(cyclopropanesulfonyl)-1 H -pyrrol-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ ⁶ ,2,5-thiadiazolidin-1, 1,3-trione; 5-{1-fluoro-3-hydroxy-7-[(3 S )-pyrrolidin-3-yl]naphthalen-2-yl}-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-{1-fluoro-3-hydroxy-7-[(3 R )-pyrrolidin-3-yl]naphthalen-2-yl}-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-(8-chloro-1-fluoro-3-hydroxy-7-methoxynaphthalen-2-yl)-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-{7-[(3,3-difluorocyclobutyl)methoxy]-1-fluoro-3-hydroxynaphthalene-2-yl}-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-(7-cyclopropyl-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-{7-[1-(cyclopropanecarbonyl)-2,5-dihydro-1 H -pyrrol-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ ⁶ ,2,5-thiadiazolidin- 1,1,3-trione; 5-(4-chloro-1-fluoro-3-hydroxy-7-methoxynaphthalen-2-yl)-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-{7-[( E )-2-cyclopropylethenyl]-1-fluoro-3-hydroxynaphthalene-2-yl}-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-{1-fluoro-3-hydroxy-7-[(1 E )-4-methylpent-1-en-1-yl]naphthalene-2-yl}-1λ ⁶ ,2,5-thiadiazolidin-1,1 ,3-trion; 5-{1-fluoro-3-hydroxy-7-[1-(pentamethylphenyl)ethenyl]naphthalen-2-yl}-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-{7-[1-(cyclopropylmethyl)-2,5-dihydro-1 H -pyrrol-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ ⁶ ,2,5-thiadiazolidin- 1,1,3-trione; 5-(4-bromo-1-fluoro-3-hydroxy-7-methoxynaphthalene-2-yl)-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-{7-[1-(2-cyclopropylethyl)-2,5-dihydro-1 H -pyrrol-3-yl]-1-fluoro-3-hydroxynaphthalene-2-yl}-1λ ^6,2,5- thiadiazolidin-1,1,3-trione; 5-{1-fluoro-3-hydroxy-7-[(1 E )-3-methoxyprop-1-en-1-yl]naphthalene-2-yl}-1λ ⁶ ,2,5-thiadiazolidin-1,1 ,3-trion; 5-[7-(2-ethoxyethoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-[1-fluoro-3-hydroxy-7-(3-methoxypropoxy)naphthalen-2-yl]-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-[7-(1,1-dioxo-1λ ⁶ -thian-4-yl)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ ⁶ ,2,5-thiadiazolidin-1,1,3- trione; 5-[1-fluoro-3-hydroxy-7-(oxan-3-yl)naphthalen-2-yl]-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-[7-(cyclopropylmethoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-(1-fluoro-3-hydroxy-7-{[1-(2,2,2-trifluoroethyl)pyrrolidin-3-yl]methyl}naphthalen-2-yl)-1λ ⁶ ,2,5-thiadiazolidin- 1,1,3-trione; 5-(1-fluoro-3-hydroxy-7-{[1-(2,2,2-trifluoroethyl)piperidin-4-yl]methyl}naphthalen-2-yl)-1λ ⁶ ,2,5-thiadiazolidin- 1,1,3-trione; 5-(1-fluoro-3-hydroxy-7-{2-[methyl(2-methylpropyl)amino]ethoxy}naphthalen-2-yl)-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione ; 5-{1-fluoro-3-hydroxy-7-[(oxolan-2-yl)methoxy]naphthalen-2-yl}-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-[1-fluoro-3-hydroxy-7-(oxolan-3-yl)naphthalen-2-yl]-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-(7-{[1-(cyclopropanesulfonyl)azetidin-3-yl]methyl}-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione ; 5-(7-{[1-(cyclopropanesulfonyl)piperidin-4-yl]methyl}-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione ; 5-[1-fluoro-3-hydroxy-7-(pyrrolidin-2-yl)naphthalen-2-yl]-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-(7-{[1-(cyclopropanesulfonyl)piperidin-3-yl]methyl}-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione ; 5-[7-(difluoromethoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-(7-{[1-(cyclopropanesulfonyl)pyrrolidin-3-yl]methyl}-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione ; 5-{1-fluoro-3-hydroxy-7-[(pyrrolidin-3-yl)methyl]naphthalene-2-yl}-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-[7-(2,5-dihydrofuran-3-yl)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-[7-(3,6-dihydro-2 H -pyran-4-yl)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ ⁶ ,2,5-thiadiazolidin-1,1,3- trione; 5-[7-(2,5-dihydro-1 H -pyrrol-3-yl)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ ⁶ ,2,5-thiadiazolidin-1,1,3- trione; 5-[1-fluoro-3-hydroxy-7-(pyridin-3-yl)naphthalen-2-yl]-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-{7-[(azetidin-3-yl)methyl]-1-fluoro-3-hydroxynaphthalene-2-yl}-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; N -(2-cyclopropylethyl)-2-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ ⁶ ,2,5-thiadiazolidin-2-yl)naphthalene-2-yl] amino}acetamide; 4-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ ⁶ ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy} -N -methylbutanamide; N -ethyl- N '-(2-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ ⁶ ,2,5-thiadiazolidin-2-yl)naphthalene-2-yl] hydroxy}ethyl)urea; 5-{1-fluoro-3-hydroxy-7-[(oxan-3-yl)methoxy]naphthalene-2-yl}-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-{7-[(1-chloro-3-hydroxypropan-2-yl)oxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ ⁶ ,2,5-thiadiazolidin-1,1,3- trione; 5-{1-fluoro-3-hydroxy-7-[(oxan-4-yl)methoxy]naphthalene-2-yl}-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-{1-fluoro-3-hydroxy-7-[(oxetan-3-yl)oxy]naphthalene-2-yl}-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-{1-fluoro-3-hydroxy-7-[1-(2,2,2-trifluoroethyl)-1,2,3,6-tetrahydropyridin-4-yl]naphthalene-2-yl}-1λ ⁶ , 2,5-thiadiazolidin-1,1,3-trione; 5-(1-fluoro-3,7-dihydroxynaphthalen-2-yl)-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-[1-fluoro-3-hydroxy-7-(2-hydroxyethoxy)naphthalene-2-yl]-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-(1-fluoro-3-hydroxy-7-propoxynaphthalen-2-yl)-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-{1-fluoro-3-hydroxy-7-[(propan-2-yl)oxy]naphthalen-2-yl}-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; {[8-Fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ ⁶ ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]amino}acetic acid; N -(2-cyclopropylethyl)-2-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ ⁶ ,2,5-thiadiazolidin-2-yl)naphthalene-2-yl] hydroxy}acetamide; N, N -diethyl-2-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ ⁶ ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy} acetamide; 5-{1-fluoro-3-hydroxy-7-[2-oxo-2-(pyrrolidin-1-yl)ethoxy]naphthalen-2-yl}-1λ ⁶ ,2,5-thiadiazolidin-1,1,3 -trione; 5-(1-fluoro-3-hydroxy-7-{[1-(methanesulfonyl)piperidin-4-yl]oxy}naphthalen-2-yl)-1λ ⁶ ,2,5-thiadiazolidin-1,1,3- trione; 5-{1-fluoro-3-hydroxy-7-[1-(oxolane-3-sulfonyl)-2,5-dihydro- 1H -pyrrol-3-yl]naphthalene-2-yl}-1λ ⁶ .2 ,5-thiadiazolidin-1,1,3-trione; 5-{1-fluoro-3-hydroxy-7-[1-(2-methoxyethanesulfonyl)-2,5-dihydro- 1H -pyrrol-3-yl]naphthalene-2-yl} ^-1λ 6.2.5 -thiadiazolidin-1,1,3-trione; 5-{1-fluoro-3-hydroxy-7-[1-(3,3,3-trifluoropropan-1-sulfonyl)-2,5-dihydro- 1H -pyrrol-3-yl]naphthalene-2-yl }-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-{1-fluoro-3-hydroxy-7-[1-(3,3,3-trifluoropropan-1-sulfonyl)-2,5-dihydro- 1H -pyrrol-3-yl]naphthalene-2-yl }-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-(1-fluoro-3-hydroxy-7-{1-[(oxan-2-yl)methanesulfonyl]-2,5-dihydro- 1H -pyrrol-3-yl}naphthalene-2-yl)-1λ ^6,2,5 -thiadiazolidin-1,1,3-trione; 5-{1-fluoro-3-hydroxy-7-[1-(4,4,4-trifluorobutan-1-sulfonyl)-2,5-dihydro- 1H -pyrrol-3-yl]naphthalene-2-yl }-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-{7-[1-(butan-1-sulfonyl)-2,5-dihydro-1 H -pyrrol-3-yl]-1-fluoro-3-hydroxynaphthalene-2-yl}-1λ ⁶ .2, 5-thiadiazolidin-1,1,3-trione; 5-(7-{1-[(1,4-dioxan-2-yl)methanesulfonyl]-2,5-dihydro- 1H -pyrrol-3-yl}-1-fluoro-3-hydroxynaphthalene-2-yl )-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-{3-[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ ⁶ ,2,5-thiadiazolidin-2-yl)naphthalene-2-yl]-2,5-dihydro -1 H -pyrrole-1-sulfonyl}pentanenitrile; 5-{1-fluoro-3-hydroxy-7-[1-(pentan-2-sulfonyl)-2,5-dihydro- 1H -pyrrol-3-yl]naphthalene-2-yl}-1λ ⁶ .2 ,5-thiadiazolidin-1,1,3-trione; 5-{7-[1-(ethanesulfonyl)-2,5-dihydro-1 H -pyrrol-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ ⁶ ,2,5-thiadiazolidin- 1,1,3-trione; 5-{1-fluoro-3-hydroxy-7-[1-(propane-2-sulfonyl)-2,5-dihydro- 1H -pyrrol-3-yl]naphthalene-2-yl}-1λ ⁶ .2 ,5-thiadiazolidin-1,1,3-trione; 5-{7-[1-(cyclopropanesulfonyl)-1,2,3,6-tetrahydropyridin-4-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ ⁶ ,2,5-thiadiazolidin-1 ,1,3-trione; N- (2-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ ⁶ ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}ethyl)oxetane -3-sulfonamide; 5-[1-fluoro-3-hydroxy-7-(piperidin-4-yl)naphthalen-2-yl]-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-{1-fluoro-3-hydroxy-7-[1-(2-methylpropan-1-sulfonyl)-2,5-dihydro- 1H -pyrrol-3-yl]naphthalene-2-yl}-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-(7-ethoxy-1-fluoro-3-hydroxynaphthalene-2-yl)-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-[7-(2,2-difluoroethoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-{7-[1-(cyclopropanesulfonyl)-1 H -pyrazol-4-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ ⁶ ,2,5-thiadiazolidin-1,1,3- trione; 5-(1-fluoro-3-hydroxy-7-{[(3 R )-1-(methanesulfonyl)pyrrolidin-3-yl]amino}naphthalen-2-yl)-1λ ⁶ ,2,5-thiadiazolidin-1 ,1,3-trione; 5-(1-fluoro-3-hydroxy-7-{[1-(methanesulfonyl)piperidin-4-yl]amino}naphthalen-2-yl)-1λ ⁶ ,2,5-thiadiazolidin-1,1,3- trione; 5-(7-{[1-(cyclopropanesulfonyl)pyrrolidin-3-yl]amino}-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione ; 5-(1-fluoro-7-{[3-fluoro-1-(methanesulfonyl)pyrrolidin-3-yl]methoxy}-3-hydroxynaphthalen-2-yl)-1λ ⁶ ,2,5-thiadiazolidin-1,1 ,3-trion; 5-{1-fluoro-3-hydroxy-7-[1-(propane-2-sulfonyl)pyrrolidin-3-yl]naphthalen-2-yl}-1λ ⁶ ,2,5-thiadiazolidin-1,1,3 -trione; 5-[7-(2-aminoethoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-{7-[1-(1,3-dimethyl- 1H -pyrazole-4-sulfonyl)-2,5-dihydro- 1H -pyrrol-3-yl]-1-fluoro-3-hydroxynaphthalene-2 -yl}-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; N -(2-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ ⁶ ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}ethyl)ethanesulfonamide ; 5-{1-fluoro-7-[1-(furan-3-sulfonyl)-2,5-dihydro- 1H -pyrrol-3-yl]-3-hydroxynaphthalene-2-yl}-1λ ⁶ .2, 5-thiadiazolidin-1,1,3-trione; 5-{1-fluoro-3-hydroxy-7-[1-(3-methylbutan-1-sulfonyl)-2,5-dihydro- 1H -pyrrol-3-yl]naphthalene-2-yl}-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 5-{1-fluoro-3-hydroxy-7-[1-(thiophene-3-sulfonyl)-2,5-dihydro- 1H -pyrrol-3-yl]naphthalene-2-yl}-1λ ⁶ .2 ,5-thiadiazolidin-1,1,3-trione; 5-{7-[1-(benzenesulfonyl)-2,5-dihydro-1 H -pyrrol-3-yl]-1-fluoro-3-hydroxynaphthalene-2-yl}-1λ ⁶ ,2,5-thiadiazolidin- 1,1,3-trione; 5-{7-[1-(cyclobutanesulfonyl)-2,5-dihydro-1 H -pyrrol-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ ⁶ ,2,5-thiadiazolidin- 1,1,3-trione; methyl (2 S )-2-amino-4-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ ^6,2,5 -thiadiazolidin-2-yl)naphthalene-2- yl]hydroxy}butanoate; 5-{7-[(3,5-dimethyl-1 H -pyrazol-4-yl)methoxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ ⁶ ,2,5-thiadiazolidin-1,1 ,3-trion; 5-[7-(3,5-dimethyl-1 H -pyrazol-4-yl)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ ⁶ ,2,5-thiadiazolidin-1,1,3- trione; 5-[7-(2-cyclohexylethoxy)-1-fluoro-3-hydroxynaphthalene-2-yl]-1λ ⁶ ,2,5-thiadiazolidin-1,1,3-trione; 2-[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ ⁶ ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]-1 H -imidazole-4-carbonitrile ; and a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, N -oxide or stereoisomer thereof. 59. A pharmaceutically acceptable composition containing a compound according to any one of paragraphs. 1-58 and a pharmaceutically acceptable carrier. 60. Composition according to claim 59, characterized in that the composition is formulated for oral administration. 61. A method of treating cancer in a patient in need thereof, comprising administering to the patient an effective amount of a compound according to any one of paragraphs. 1-58 in combination with an additional therapeutic agent. 62. A method of treating cancer in a patient in need thereof, comprising administering to the patient an effective amount of a pharmaceutically acceptable composition according to claim 59 or 60 in combination with an additional therapeutic agent. 63. The method according to claim 61 or 62, characterized in that the additional therapeutic agent is an immunotherapeutic agent. 64. The method of claim 63, wherein the immunotherapeutic agent is selected from the group consisting of an anti-PD-1 antibody, an anti-PD-L1 antibody, and an anti-CTLA-4 antibody. 65. A method of treating cancer in a patient in need thereof, comprising administering to the patient an effective amount of a compound according to any one of paragraphs. 1-58. 66. A method of treating cancer in a patient in need thereof, comprising administering to the patient an effective amount of a pharmaceutically acceptable composition according to claim 59 or 60. 67. A method of treating type 2 diabetes in a patient in need thereof, comprising administering to the patient an effective amount of a compound according to any one of paragraphs. 1-58 or compositions according to claim 59 or 60. 68. A method for treating and/or controlling obesity in a patient in need thereof, comprising administering to the patient an effective amount of a compound according to any one of paragraphs. 1-58 or compositions according to claim 59 or 60. 69. A method of suppressing further weight gain in an overweight or obese patient in need thereof, comprising administering to the patient an effective amount of a compound according to any one of paragraphs. 1-58 or compositions according to claim 59 or 60. 70. A method of treating a metabolic disorder in a patient in need thereof, comprising administering to the patient an effective amount of a compound according to any one of paragraphs. 1-58 or compositions according to claim 59 or 60.